Genentech Biooncology Genentech Biooncology Genentech Biooncology

Explore Currently Enrolling Genentech and Roche Clinical Trials in Oncology

Search for clinical trials by making selections below.

–

Tumor Type View All

Breast Gastrointestinal Genitourinary Gynecologic Hematology Lung Melanoma Solid Tumor

Phase

III II I

Molecule*

Select...▼
Antibody drug conjugate (RG6109) Antibody drug conjugate (RG6148) Anti-MUC16 TDC (RG7882) Atezolizumab (anti-PDL1 MAb) (RG7446) BET inhibitor (TEN-010, RG6146) Bevacizumab (anti-VEGF MAb) CD20 x CD3 (RG6026) Cergutuzumab amunaleukin (CEA-IL2v) (RG7813) ChK1 inhibitor (GDC-0575, RG7741) Cibisatamab (CEA x CD3) (RG7802) Cobimetinib (MEK inhibitor) (RG7421) Codrituzumab (anti–glypican 3 MAb) (CHU, RG7686) Emactuzumab (anti–CSF-1R MAb) (RG7155) Entrectinib (ROS1/TRK inhibitor) (RXDX-101, RG6268) FAP-4-1BBL FP (RG7827) FAP-DR5 biMAb (RG7386) FAP-IL2v FP (RG7461) Fixed dose combination SC pertuzumab + trastuzumab (anti-HER2 MAb) (RG6264) Glypican-3 x CD3 (CHU) HER2 x CD3 (RG6194) Idasanutlin (MDM2 antagonist) (RG7388) Individualized NeoAntigen Specific Immunotherapy (iNeST) (RG6180) Ipatasertib (AKT inhibitor) (GDC-0068, RG7440) Monoclonal antibody (RG6123) Monoclonal antibody (RG6160) Mosunetuzumab (CD20 x CD3) (RG7828) Obinutuzumab Pan-RAF inhibitor (RG6185) PD-1 x TIM3 (RG7769) PI3K inhibitor (GDC-0077, RG6114) PI3K inhibitor (RG6114) Polatuzumab vedotin (anti-CD79b ADC) (RG7596) Raf/MEK dual inhibitor (CHU) Selective estrogen receptor degrader (SERD[3]) (GDC-9545, RG6171) Selicrelumab (CD40 MAb) (RG7876) Taselisib (PI3K inhibitor) (GDC-0032, RG7604) Tiragolumab (anti-TIGIT MAb) (RG6058) Vanucizumab (ANG2-VEGF biMAb) (RG7221) Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601)

US Region

International

Region

Select...▼
Clear All
View Results
Expand +

Tumor Type: Breast, Gastrointestinal, Genitourinary, Gynecologic, Hematology, Lung, Melanoma, Solid Tumor

Phase: PHASE II

Region:

Molecule: Polatuzumab vedotin (anti-CD79b ADC) (RG7596)

For more information about recruiting clinical trials, please call the Trial Information Support Line for US Clinical Trial information at 888-662-6728 or visit ClinicalTrials.gov.
Email your search results to yourself.
Clear All
View Results
Arrange by:
Tumor Type Ascending ▲ Tumor Type Descending ▼ Phase Ascending ▲ Phase Descending ▼ Molecule Ascending ▲ Molecule Descending ▼ Location Ascending ▲ Location Descending ▼
Contact Genentech Medical Affairs
Tumor Type Phase Molecule* Location Study Contact
Tumor
Type		 Phase Molecule* Location
Hematology II, I Mosunetuzumab (CD20 x CD3) (RG7828), Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab AZ NCT03677141—A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma
Hematology II, I Mosunetuzumab (CD20 x CD3) (RG7828), Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab AZ
NCT03677141—A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma
Tumor
Type		 Phase Molecule* Location
Hematology II, I Mosunetuzumab (CD20 x CD3) (RG7828), Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab FL NCT03677141—A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma
Hematology II, I Mosunetuzumab (CD20 x CD3) (RG7828), Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab FL
NCT03677141—A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma
Tumor
Type		 Phase Molecule* Location
Hematology II, I Mosunetuzumab (CD20 x CD3) (RG7828), Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab KS NCT03677141—A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma
Hematology II, I Mosunetuzumab (CD20 x CD3) (RG7828), Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab KS
NCT03677141—A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma
Tumor
Type		 Phase Molecule* Location
Hematology II, I Mosunetuzumab (CD20 x CD3) (RG7828), Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab TX NCT03677141—A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma
Hematology II, I Mosunetuzumab (CD20 x CD3) (RG7828), Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab TX
NCT03677141—A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma
Tumor
Type		 Phase Molecule* Location
Hematology II, I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab AU NCT02257567—A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma
Hematology II, I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab AU
NCT02257567—A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma
Tumor
Type		 Phase Molecule* Location
Hematology II, I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab CA NCT02257567—A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma
Hematology II, I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab CA
NCT02257567—A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma
Tumor
Type		 Phase Molecule* Location
Hematology II, I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab CA NCT02257567—A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma
Hematology II, I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab CA
NCT02257567—A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma
Tumor
Type		 Phase Molecule* Location
Hematology II, I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab FL NCT02257567—A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma
Hematology II, I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab FL
NCT02257567—A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma
Tumor
Type		 Phase Molecule* Location
Hematology II, I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab FR NCT02257567—A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma
Hematology II, I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab FR
NCT02257567—A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma
Tumor
Type		 Phase Molecule* Location
Hematology II, I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab GB NCT02257567—A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma
Hematology II, I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab GB
NCT02257567—A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma
Tumor
Type		 Phase Molecule* Location
Hematology II, I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab HU NCT02257567—A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma
Hematology II, I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab HU
NCT02257567—A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma
Tumor
Type		 Phase Molecule* Location
Hematology II, I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab IT NCT02257567—A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma
Hematology II, I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab IT
NCT02257567—A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma
Tumor
Type		 Phase Molecule* Location
Hematology II, I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab KR NCT02257567—A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma
Hematology II, I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab KR
NCT02257567—A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma
Tumor
Type		 Phase Molecule* Location
Hematology II, I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab NA NCT02257567—A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma
Hematology II, I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab NA
NCT02257567—A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma
Tumor
Type		 Phase Molecule* Location
Hematology II, I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab NY NCT02257567—A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma
Hematology II, I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab NY
NCT02257567—A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma
Tumor
Type		 Phase Molecule* Location
Hematology II, I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab TR NCT02257567—A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma
Hematology II, I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab TR
NCT02257567—A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma
1 of 16 clinical trials ▼
1-4 of 16 clinical trials ▼
ClickTap on the NCT numbers above to visit ClinicalTrials.gov for further details about each trial, including eligibility criteria, primary and secondary outcome measures, and contacts and locations.

Current as of June 25, 2019. The trial information is taken from ClinicalTrials.gov. The list of international studies is not comprehensive; only international studies that also include actively enrolling US sites are listed.

These compounds and/or uses are investigational and have not been approved by the US Food and Drug Administration. Some molecules are currently being investigated for potential use in multiple tumor types. Efficacy and safety have not been established. The information presented should not be construed as a recommendation for use.

*Only Genentech/Roche molecules are shown in this column. Please see ClinicalTrials.gov website for a complete list of agents/interventions used in each study.

Genentech Genentech
Contact Us | Privacy Policy | Terms & Conditions
© 2017 Genentech USA, Inc. All rights reserved. | BIO/102115/0195(1)
This website is intended for US healthcare professionals only.
This website is intended for US healthcare professionals and contains information on investigational compounds and drug uses that have not been approved by the FDA. Click "OK" if you are a healthcare professional and wish to proceed.
CancelOK
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech. Genentech makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.
CancelContinue
The list of international studies is not comprehensive; only international studies that also include actively enrolling US sites are listed.

Click "OK" if you wish to proceed.
CancelOK